Bloodstream infections caused by metallo-β-lactamase/ Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: Risk factors for infection and impact of type of resistance on outcomes

Infection Control and Hospital Epidemiology

Volumn 31, Issue 12, 2010, Pages 1250-1256

  Mouloudi, Eleni ^a   Protonotariou, Euthymia ^a   Zagorianou, Alexia ^a   Iosifidis, Elias ^b   Karapanagiotou, Areti ^a   Giasnetsova, Tatiana ^a   Tsioka, Agoritsa ^a   Roilides, Emmanuel ^b   Sofianou, Danai ^a   Gritsi Gerogianni, Nikoleta ^a  

^a Aristotle University and Hippokration General Hospital   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CARBAPENEMASE; CEPHALOSPORIN DERIVATIVE; METALLO BETA LACTAMASE; QUINOLONE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; CASE CONTROL STUDY; CONTROLLED STUDY; DEATH; FEMALE; GREECE; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; RISK FACTOR; SURVIVOR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; APACHE; BACTEREMIA; BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEMS; CASE-CONTROL STUDIES; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GREECE; HUMANS; INTENSIVE CARE UNITS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; METALLOPROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78649926918     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/657135     Document Type: Article

References (29)

1. Gasink LB, Edelstein PH, Lautenbach E, Synnestvedt M, Fishman NO. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase- producing K. pneumoniae. Infect Control Hosp Epidemiol 2009;30:1180-1185.
2. Pournaras S, Iosifidis E, Roilides E. Advances in antibacterial therapy against emerging bacterial pathogens. Semin Hematol 2009;46:198-211.
3. Cagatay AA, Ozcan PE, Gulec L, et al. Risk factors for mortality of nosocomial bacteraemia in intensive care units. Med Princ Pract 2007;16: 187-192.
4. Pitout JD, Laupland KB. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008;8:159-166.
5. Bratu S, Landman D, Haag R, et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 2005;165:1430-1435.
6. Souli M, Galani I, Antoniadou A, et al. An outbreak of infection due to β-lactamase Klebsiella pneumoniae carbapenemase 2-producing K. pneumoniae in a Greek university hospital: molecular characterization, epidemiology, and outcomes. Clin Infect Dis 2010;50:364-373.
7. Marchaim D, Navon-Venezia S, Schwaber MJ, Carmeli Y. Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes. Antimicrob Agents Chemother 2008;52:1413-1418.
8. Hall BG, Barlow M. Revised Ambler classification of β-lactamases. J Antimicrob Chemother 2005;55:1050-1051.
9. Queenan AM, Bush K. Carbapenemases: the versatile β-lactamases. Clin Microbiol Rev 2007;20:440-458.
10. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008;29:1099-1106.
11. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition onmortality. Antimicrob Agents Chemother 2008;52:1028-1033. (Pubitemid 351358384)
12. Falagas ME, Rafailidis PI, Kofteridis D, et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. J Antimicrob Chemother 2007;60:1124-1130. (Pubitemid 47617764)
13. Hussein K, Sprecher H, Mashiach T, Oren I, Kassis I, Finkelstein R. Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns. Infect Control Hosp Epidemiol 2009;30:666-671.
14. Kwak YG, Choi SH, Choo EJ, et al. Risk factors for the acquisition of carbapenem-resistant Klebsiella pneumoniae among hospitalized patients. Microb Drug Resist 2005;11:165-169.
15. Daikos GL, Petrikkos P, Psichogiou M, et al. Prospective observational study of the impact of VIM-1 metallo-β-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother 2009;53:1868-1873.
16. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-829.
17. Vincent JL, Moreno R, Takala J, et al. The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. Intensive Care Med 1996;22:707-710.
18. Clinical and Laboratory Standard Institute (CLSI). Performance standards for antimicrobial susceptibility testing: 17th informational supplement. Wayne, PA: CLSI; 2007. CLSI document M100-S117.
19. European Committee on Antimicrobial Susceptibility Testing website. http://www.eucast.org/. Accessed May 17, 2010.
20. VIM-1 gene in the community. Int J Antimicrob Agents 2009;34:187-188.
21. VIM-12 in a university hospital. J Clin Microbiol 2008;46:1005-1008.
22. National Center for Biotechnology Information website. http://www .ncbi.nlm.nih.gov/. Accessed May 17, 2010.
23. ClustalW2. European Bioinformatics Institute, European Molecular Biology Laboratory, website. http://www.ebi.ac.uk/Tools/clustalw2/index .html. Accessed May 17, 2010.
24. Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006;42:692-699.
25. Falagas ME, Kopterides P, Siempos II. Attributable mortality of Acinetobacter baumannii infection among critically ill patients [letter]. Clin Infect Dis 2006;43:389; reply 389-390.
26. Giske CG, Monnet DL, Cars O, Carmeli Y. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 2008;52:813-821. (Pubitemid 351358357)
27. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005;40:1333-1341.
28. Souli M, Kontopidou FV, Papadomichelakis E, Galani I, Armaganidis A, Giamarellou H. Clinical experience of serious infections caused by Enterobacteriaceae producing VIM-1 metallo-β-lactamase in a Greek university hospital. Clin Infect Dis 2008;46:847-854.
29. Falagas ME, Kopterides P. Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infect 2006;64:7-15.